MovDisordV3, PascalFrancis, Corpus, bibRecord, 000B62

Double-Blind Study of Pardoprunox, a New Partial Dopamine Agonist, in Early Parkinson's Disease

Identifieur interne : 000B62 ( PascalFrancis/Corpus ); précédent : 000B61; suivant : 000B63

Double-Blind Study of Pardoprunox, a New Partial Dopamine Agonist, in Early Parkinson's Disease

Auteurs : Juliana Bronzova ; Cristina Sampaio ; Robert A. Hauser ; Anthony E. Lang ; Olivier Rascol ; Ad Theeuwes ; Serge V. Van De Witte ; Guus Van Scharrenburg

Source :

Movement disorders [ 0885-3185 ] ; 2010.

RBID : Pascal:10-0233116

Descripteurs français

Pascal (Inist)
- Maladie de Parkinson, Pathologie du système nerveux, Etude double insu, Pardoprunox, Agoniste partiel, Stimulant dopaminergique, Essai clinique.

English descriptors

KwdEn :
- Clinical trial, Dopamine agonist, Double blind study, Nervous system diseases, Pardoprunox, Parkinson disease, Partial agonist.

Abstract

This study examined the efficacy and safety of the partial dopamine agonist, pardoprunox (SLV308), in the treatment of patients with early Parkinson's disease (PD). Patients were randomized to receive pardoprunox (n = 69) or placebo (n = 70). Pardoprunox was titrated to each patient's optimal dose (9-45 mg/d) over 2 to 6 weeks and then maintained at this dose for a further 3 weeks. Concomitant anti-Parkinson treatment was not permitted. In the primary analysis, Unified PD Rating Scale (UPDRS)-Motor score was improved in pardoprunox-treated patients (overall mean dose 23.8 mg/d; -7.3 points), as compared with placebo (-3.0 points; P = 0.0001), from baseline to end point. At end point, there were more responders (≥0:30% reduction in UPDRS-Motor score) in the pardoprunox group (50.7%) than in the placebo group (15.7%; P < 0.0001). In other secondary analyses, UPDRS-activities of daily living (ADL) and -ADL+Motor scores were also significantly more improved in the pardoprunox group. Nausea was reported by 32 of 68 (47.1%) pardoprunox-treated patients (vs. 3/70, 4.3%, placebo-treated patients), with dizziness, somnolence, headache, and asthenia also reported by ≥10 patients. In this exploratory proof-of-concept study, pardoprunox significantly improved motor function in patients with early PD. The efficacy and safety profile of pardoprunox justifies its further investigation in PD.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 25`
A06				`@2 6`
A08	`01`	`1`	`ENG`	`@1 Double-Blind Study of Pardoprunox, a New Partial Dopamine Agonist, in Early Parkinson's Disease`
A11	`01`	`1`		`@1 BRONZOVA (Juliana)`
A11	`02`	`1`		`@1 SAMPAIO (Cristina)`
A11	`03`	`1`		`@1 HAUSER (Robert A.)`
A11	`04`	`1`		`@1 LANG (Anthony E.)`
A11	`05`	`1`		`@1 RASCOL (Olivier)`
A11	`06`	`1`		`@1 THEEUWES (Ad)`
A11	`07`	`1`		`@1 VAN DE WITTE (Serge V.)`
A11	`08`	`1`		`@1 VAN SCHARRENBURG (Guus)`
A14	`01`			`@1 Solvay Pharmaceuticals B.V., Clinical Neuroscience Department @2 Weesp @3 NLD @Z 1 aut. @Z 6 aut. @Z 7 aut. @Z 8 aut.`
A14	`02`			`@1 Department of Pharmacology, Faculdade de Medicina de Lisboa @2 Lisbon @3 PRT @Z 2 aut.`
A14	`03`			`@1 Departments of Neurology, Pharmacology and Experimental Therapeutics, University of South Florida @2 Tampa, Florida @3 USA @Z 3 aut.`
A14	`04`			`@1 Division of Neurology, Toronto Western Hospital, University of Toronto @2 Toronto, Ontario @3 CAN @Z 4 aut.`
A14	`05`			`@1 Departments of Neurosciences and Clinical Pharmacology, Clinical Investigation Center, University Hospital of Toulouse, INSERM UMR 825 @2 Toulouse @3 FRA @Z 5 aut.`
A20				`@1 738-746`
A21				`@1 2010`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000181078480110`
A44				`@0 0000 @1 © 2010 INIST-CNRS. All rights reserved.`
A45				`@0 34 ref.`
A47	`01`	`1`		`@0 10-0233116`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 This study examined the efficacy and safety of the partial dopamine agonist, pardoprunox (SLV308), in the treatment of patients with early Parkinson's disease (PD). Patients were randomized to receive pardoprunox (n = 69) or placebo (n = 70). Pardoprunox was titrated to each patient's optimal dose (9-45 mg/d) over 2 to 6 weeks and then maintained at this dose for a further 3 weeks. Concomitant anti-Parkinson treatment was not permitted. In the primary analysis, Unified PD Rating Scale (UPDRS)-Motor score was improved in pardoprunox-treated patients (overall mean dose 23.8 mg/d; -7.3 points), as compared with placebo (-3.0 points; P = 0.0001), from baseline to end point. At end point, there were more responders (≥0:30% reduction in UPDRS-Motor score) in the pardoprunox group (50.7%) than in the placebo group (15.7%; P < 0.0001). In other secondary analyses, UPDRS-activities of daily living (ADL) and -ADL+Motor scores were also significantly more improved in the pardoprunox group. Nausea was reported by 32 of 68 (47.1%) pardoprunox-treated patients (vs. 3/70, 4.3%, placebo-treated patients), with dizziness, somnolence, headache, and asthenia also reported by ≥10 patients. In this exploratory proof-of-concept study, pardoprunox significantly improved motor function in patients with early PD. The efficacy and safety profile of pardoprunox justifies its further investigation in PD.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 02`
C03	`02`	`X`	`ENG`	`@0 Nervous system diseases @5 02`
C03	`02`	`X`	`SPA`	`@0 Sistema nervioso patología @5 02`
C03	`03`	`X`	`FRE`	`@0 Etude double insu @5 09`
C03	`03`	`X`	`ENG`	`@0 Double blind study @5 09`
C03	`03`	`X`	`SPA`	`@0 Estudio doble ciego @5 09`
C03	`04`	`X`	`FRE`	`@0 Pardoprunox @2 FR @5 10`
C03	`04`	`X`	`ENG`	`@0 Pardoprunox @2 FR @5 10`
C03	`04`	`X`	`SPA`	`@0 Pardoprunox @2 FR @5 10`
C03	`05`	`X`	`FRE`	`@0 Agoniste partiel @5 11`
C03	`05`	`X`	`ENG`	`@0 Partial agonist @5 11`
C03	`05`	`X`	`SPA`	`@0 Agonista parcial @5 11`
C03	`06`	`X`	`FRE`	`@0 Stimulant dopaminergique @5 12`
C03	`06`	`X`	`ENG`	`@0 Dopamine agonist @5 12`
C03	`06`	`X`	`SPA`	`@0 Estimulante dopaminérgico @5 12`
C03	`07`	`X`	`FRE`	`@0 Essai clinique @5 13`
C03	`07`	`X`	`ENG`	`@0 Clinical trial @5 13`
C03	`07`	`X`	`SPA`	`@0 Ensayo clínico @5 13`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
N21				`@1 158`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 10-0233116 INIST
ET :	Double-Blind Study of Pardoprunox, a New Partial Dopamine Agonist, in Early Parkinson's Disease
AU :	BRONZOVA (Juliana); SAMPAIO (Cristina); HAUSER (Robert A.); LANG (Anthony E.); RASCOL (Olivier); THEEUWES (Ad); VAN DE WITTE (Serge V.); VAN SCHARRENBURG (Guus)
AF :	Solvay Pharmaceuticals B.V., Clinical Neuroscience Department/Weesp/Pays-Bas (1 aut., 6 aut., 7 aut., 8 aut.); Department of Pharmacology, Faculdade de Medicina de Lisboa/Lisbon/Portugal (2 aut.); Departments of Neurology, Pharmacology and Experimental Therapeutics, University of South Florida/Tampa, Florida/Etats-Unis (3 aut.); Division of Neurology, Toronto Western Hospital, University of Toronto/Toronto, Ontario/Canada (4 aut.); Departments of Neurosciences and Clinical Pharmacology, Clinical Investigation Center, University Hospital of Toulouse, INSERM UMR 825/Toulouse/France (5 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2010; Vol. 25; No. 6; Pp. 738-746; Bibl. 34 ref.
LA :	Anglais
EA :	This study examined the efficacy and safety of the partial dopamine agonist, pardoprunox (SLV308), in the treatment of patients with early Parkinson's disease (PD). Patients were randomized to receive pardoprunox (n = 69) or placebo (n = 70). Pardoprunox was titrated to each patient's optimal dose (9-45 mg/d) over 2 to 6 weeks and then maintained at this dose for a further 3 weeks. Concomitant anti-Parkinson treatment was not permitted. In the primary analysis, Unified PD Rating Scale (UPDRS)-Motor score was improved in pardoprunox-treated patients (overall mean dose 23.8 mg/d; -7.3 points), as compared with placebo (-3.0 points; P = 0.0001), from baseline to end point. At end point, there were more responders (≥0:30% reduction in UPDRS-Motor score) in the pardoprunox group (50.7%) than in the placebo group (15.7%; P < 0.0001). In other secondary analyses, UPDRS-activities of daily living (ADL) and -ADL+Motor scores were also significantly more improved in the pardoprunox group. Nausea was reported by 32 of 68 (47.1%) pardoprunox-treated patients (vs. 3/70, 4.3%, placebo-treated patients), with dizziness, somnolence, headache, and asthenia also reported by ≥10 patients. In this exploratory proof-of-concept study, pardoprunox significantly improved motor function in patients with early PD. The efficacy and safety profile of pardoprunox justifies its further investigation in PD.
CC :	002B17; 002B17G
FD :	Maladie de Parkinson; Pathologie du système nerveux; Etude double insu; Pardoprunox; Agoniste partiel; Stimulant dopaminergique; Essai clinique
FG :	Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central
ED :	Parkinson disease; Nervous system diseases; Double blind study; Pardoprunox; Partial agonist; Dopamine agonist; Clinical trial
EG :	Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease
SD :	Parkinson enfermedad; Sistema nervioso patología; Estudio doble ciego; Pardoprunox; Agonista parcial; Estimulante dopaminérgico; Ensayo clínico
LO :	INIST-20953.354000181078480110
ID :	10-0233116

Links to Exploration step

Pascal:10-0233116

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Double-Blind Study of Pardoprunox, a New Partial Dopamine Agonist, in Early Parkinson's Disease</title>
<author><name sortKey="Bronzova, Juliana" sort="Bronzova, Juliana" uniqKey="Bronzova J" first="Juliana" last="Bronzova">Juliana Bronzova</name>
<affiliation><inist:fA14 i1="01"><s1>Solvay Pharmaceuticals B.V., Clinical Neuroscience Department</s1>
<s2>Weesp</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Pharmacology, Faculdade de Medicina de Lisboa</s1>
<s2>Lisbon</s2>
<s3>PRT</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation><inist:fA14 i1="03"><s1>Departments of Neurology, Pharmacology and Experimental Therapeutics, University of South Florida</s1>
<s2>Tampa, Florida</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation><inist:fA14 i1="04"><s1>Division of Neurology, Toronto Western Hospital, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation><inist:fA14 i1="05"><s1>Departments of Neurosciences and Clinical Pharmacology, Clinical Investigation Center, University Hospital of Toulouse, INSERM UMR 825</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Theeuwes, Ad" sort="Theeuwes, Ad" uniqKey="Theeuwes A" first="Ad" last="Theeuwes">Ad Theeuwes</name>
<affiliation><inist:fA14 i1="01"><s1>Solvay Pharmaceuticals B.V., Clinical Neuroscience Department</s1>
<s2>Weesp</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Van De Witte, Serge V" sort="Van De Witte, Serge V" uniqKey="Van De Witte S" first="Serge V." last="Van De Witte">Serge V. Van De Witte</name>
<affiliation><inist:fA14 i1="01"><s1>Solvay Pharmaceuticals B.V., Clinical Neuroscience Department</s1>
<s2>Weesp</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Van Scharrenburg, Guus" sort="Van Scharrenburg, Guus" uniqKey="Van Scharrenburg G" first="Guus" last="Van Scharrenburg">Guus Van Scharrenburg</name>
<affiliation><inist:fA14 i1="01"><s1>Solvay Pharmaceuticals B.V., Clinical Neuroscience Department</s1>
<s2>Weesp</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">10-0233116</idno>
<date when="2010">2010</date>
<idno type="stanalyst">PASCAL 10-0233116 INIST</idno>
<idno type="RBID">Pascal:10-0233116</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000B62</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Double-Blind Study of Pardoprunox, a New Partial Dopamine Agonist, in Early Parkinson's Disease</title>
<author><name sortKey="Bronzova, Juliana" sort="Bronzova, Juliana" uniqKey="Bronzova J" first="Juliana" last="Bronzova">Juliana Bronzova</name>
<affiliation><inist:fA14 i1="01"><s1>Solvay Pharmaceuticals B.V., Clinical Neuroscience Department</s1>
<s2>Weesp</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Pharmacology, Faculdade de Medicina de Lisboa</s1>
<s2>Lisbon</s2>
<s3>PRT</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation><inist:fA14 i1="03"><s1>Departments of Neurology, Pharmacology and Experimental Therapeutics, University of South Florida</s1>
<s2>Tampa, Florida</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation><inist:fA14 i1="04"><s1>Division of Neurology, Toronto Western Hospital, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation><inist:fA14 i1="05"><s1>Departments of Neurosciences and Clinical Pharmacology, Clinical Investigation Center, University Hospital of Toulouse, INSERM UMR 825</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Theeuwes, Ad" sort="Theeuwes, Ad" uniqKey="Theeuwes A" first="Ad" last="Theeuwes">Ad Theeuwes</name>
<affiliation><inist:fA14 i1="01"><s1>Solvay Pharmaceuticals B.V., Clinical Neuroscience Department</s1>
<s2>Weesp</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Van De Witte, Serge V" sort="Van De Witte, Serge V" uniqKey="Van De Witte S" first="Serge V." last="Van De Witte">Serge V. Van De Witte</name>
<affiliation><inist:fA14 i1="01"><s1>Solvay Pharmaceuticals B.V., Clinical Neuroscience Department</s1>
<s2>Weesp</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Van Scharrenburg, Guus" sort="Van Scharrenburg, Guus" uniqKey="Van Scharrenburg G" first="Guus" last="Van Scharrenburg">Guus Van Scharrenburg</name>
<affiliation><inist:fA14 i1="01"><s1>Solvay Pharmaceuticals B.V., Clinical Neuroscience Department</s1>
<s2>Weesp</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Clinical trial</term>
<term>Dopamine agonist</term>
<term>Double blind study</term>
<term>Nervous system diseases</term>
<term>Pardoprunox</term>
<term>Parkinson disease</term>
<term>Partial agonist</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term>
<term>Pathologie du   système nerveux</term>
<term>Etude double insu</term>
<term>Pardoprunox</term>
<term>Agoniste partiel</term>
<term>Stimulant dopaminergique</term>
<term>Essai clinique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">This study examined the efficacy and safety of the partial dopamine agonist, pardoprunox (SLV308), in the treatment of patients with early Parkinson's disease (PD). Patients were randomized to receive pardoprunox (n = 69) or placebo (n = 70). Pardoprunox was titrated to each patient's optimal dose (9-45 mg/d) over 2 to 6 weeks and then maintained at this dose for a further 3 weeks. Concomitant anti-Parkinson treatment was not permitted. In the primary analysis, Unified PD Rating Scale (UPDRS)-Motor score was improved in pardoprunox-treated patients (overall mean dose 23.8 mg/d; -7.3 points), as compared with placebo (-3.0 points; P = 0.0001), from baseline to end point. At end point, there were more responders (≥0:30% reduction in UPDRS-Motor score) in the pardoprunox group (50.7%) than in the placebo group (15.7%; P < 0.0001). In other secondary analyses, UPDRS-activities of daily living (ADL) and -ADL+Motor scores were also significantly more improved in the pardoprunox group. Nausea was reported by 32 of 68 (47.1%) pardoprunox-treated patients (vs. 3/70, 4.3%, placebo-treated patients), with dizziness, somnolence, headache, and asthenia also reported by ≥10 patients. In this exploratory proof-of-concept study, pardoprunox significantly improved motor function in patients with early PD. The efficacy and safety profile of pardoprunox justifies its further investigation in PD.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>25</s2>
</fA05>
<fA06><s2>6</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Double-Blind Study of Pardoprunox, a New Partial Dopamine Agonist, in Early Parkinson's Disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>BRONZOVA (Juliana)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>SAMPAIO (Cristina)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>HAUSER (Robert A.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>LANG (Anthony E.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>RASCOL (Olivier)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>THEEUWES (Ad)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>VAN DE WITTE (Serge V.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>VAN SCHARRENBURG (Guus)</s1>
</fA11>
<fA14 i1="01"><s1>Solvay Pharmaceuticals B.V., Clinical Neuroscience Department</s1>
<s2>Weesp</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Pharmacology, Faculdade de Medicina de Lisboa</s1>
<s2>Lisbon</s2>
<s3>PRT</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Departments of Neurology, Pharmacology and Experimental Therapeutics, University of South Florida</s1>
<s2>Tampa, Florida</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Division of Neurology, Toronto Western Hospital, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Departments of Neurosciences and Clinical Pharmacology, Clinical Investigation Center, University Hospital of Toulouse, INSERM UMR 825</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA20><s1>738-746</s1>
</fA20>
<fA21><s1>2010</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000181078480110</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2010 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>34 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>10-0233116</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>This study examined the efficacy and safety of the partial dopamine agonist, pardoprunox (SLV308), in the treatment of patients with early Parkinson's disease (PD). Patients were randomized to receive pardoprunox (n = 69) or placebo (n = 70). Pardoprunox was titrated to each patient's optimal dose (9-45 mg/d) over 2 to 6 weeks and then maintained at this dose for a further 3 weeks. Concomitant anti-Parkinson treatment was not permitted. In the primary analysis, Unified PD Rating Scale (UPDRS)-Motor score was improved in pardoprunox-treated patients (overall mean dose 23.8 mg/d; -7.3 points), as compared with placebo (-3.0 points; P = 0.0001), from baseline to end point. At end point, there were more responders (≥0:30% reduction in UPDRS-Motor score) in the pardoprunox group (50.7%) than in the placebo group (15.7%; P < 0.0001). In other secondary analyses, UPDRS-activities of daily living (ADL) and -ADL+Motor scores were also significantly more improved in the pardoprunox group. Nausea was reported by 32 of 68 (47.1%) pardoprunox-treated patients (vs. 3/70, 4.3%, placebo-treated patients), with dizziness, somnolence, headache, and asthenia also reported by ≥10 patients. In this exploratory proof-of-concept study, pardoprunox significantly improved motor function in patients with early PD. The efficacy and safety profile of pardoprunox justifies its further investigation in PD.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Etude double insu</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Double blind study</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Estudio doble ciego</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Pardoprunox</s0>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Pardoprunox</s0>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Pardoprunox</s0>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Agoniste partiel</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Partial agonist</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Agonista parcial</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Stimulant dopaminergique</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Dopamine agonist</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Estimulante dopaminérgico</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Essai clinique</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Clinical trial</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Ensayo clínico</s0>
<s5>13</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fN21><s1>158</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 10-0233116 INIST</NO>
<ET>Double-Blind Study of Pardoprunox, a New Partial Dopamine Agonist, in Early Parkinson's Disease</ET>
<AU>BRONZOVA (Juliana); SAMPAIO (Cristina); HAUSER (Robert A.); LANG (Anthony E.); RASCOL (Olivier); THEEUWES (Ad); VAN DE WITTE (Serge V.); VAN SCHARRENBURG (Guus)</AU>
<AF>Solvay Pharmaceuticals B.V., Clinical Neuroscience Department/Weesp/Pays-Bas (1 aut., 6 aut., 7 aut., 8 aut.); Department of Pharmacology, Faculdade de Medicina de Lisboa/Lisbon/Portugal (2 aut.); Departments of Neurology, Pharmacology and Experimental Therapeutics, University of South Florida/Tampa, Florida/Etats-Unis (3 aut.); Division of Neurology, Toronto Western Hospital, University of Toronto/Toronto, Ontario/Canada (4 aut.); Departments of Neurosciences and Clinical Pharmacology, Clinical Investigation Center, University Hospital of Toulouse, INSERM UMR 825/Toulouse/France (5 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2010; Vol. 25; No. 6; Pp. 738-746; Bibl. 34 ref.</SO>
<LA>Anglais</LA>
<EA>This study examined the efficacy and safety of the partial dopamine agonist, pardoprunox (SLV308), in the treatment of patients with early Parkinson's disease (PD). Patients were randomized to receive pardoprunox (n = 69) or placebo (n = 70). Pardoprunox was titrated to each patient's optimal dose (9-45 mg/d) over 2 to 6 weeks and then maintained at this dose for a further 3 weeks. Concomitant anti-Parkinson treatment was not permitted. In the primary analysis, Unified PD Rating Scale (UPDRS)-Motor score was improved in pardoprunox-treated patients (overall mean dose 23.8 mg/d; -7.3 points), as compared with placebo (-3.0 points; P = 0.0001), from baseline to end point. At end point, there were more responders (≥0:30% reduction in UPDRS-Motor score) in the pardoprunox group (50.7%) than in the placebo group (15.7%; P < 0.0001). In other secondary analyses, UPDRS-activities of daily living (ADL) and -ADL+Motor scores were also significantly more improved in the pardoprunox group. Nausea was reported by 32 of 68 (47.1%) pardoprunox-treated patients (vs. 3/70, 4.3%, placebo-treated patients), with dizziness, somnolence, headache, and asthenia also reported by ≥10 patients. In this exploratory proof-of-concept study, pardoprunox significantly improved motor function in patients with early PD. The efficacy and safety profile of pardoprunox justifies its further investigation in PD.</EA>
<CC>002B17; 002B17G</CC>
<FD>Maladie de Parkinson; Pathologie du   système nerveux; Etude double insu; Pardoprunox; Agoniste partiel; Stimulant dopaminergique; Essai clinique</FD>
<FG>Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du   système nerveux central</FG>
<ED>Parkinson disease; Nervous system diseases; Double blind study; Pardoprunox; Partial agonist; Dopamine agonist; Clinical trial</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease</EG>
<SD>Parkinson enfermedad; Sistema nervioso patología; Estudio doble ciego; Pardoprunox; Agonista parcial; Estimulante dopaminérgico; Ensayo clínico</SD>
<LO>INIST-20953.354000181078480110</LO>
<ID>10-0233116</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B62 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000B62 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:10-0233116
   |texte=   Double-Blind Study of Pardoprunox, a New Partial Dopamine Agonist, in Early Parkinson's Disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Double-Blind Study of Pardoprunox, a New Partial Dopamine Agonist, in Early Parkinson's Disease

Double-Blind Study of Pardoprunox, a New Partial Dopamine Agonist, in Early Parkinson's Disease

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri